Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from Patrys Limited ( (AU:PAB) ).
Patrys Limited has executed a strategic expansion of its pipeline by acquiring 100% of Reliis Pty Ltd, adding RLS-2201, a proprietary injectable quetiapine formulation for treating delirium in critically ill, elderly and palliative-care patients, where no approved acute-care therapies currently exist. The RLS-2201 asset offers a shorter, more predictable development and regulatory pathway, with potential to leverage streamlined approval routes and generate human data sooner than the company’s biologics programs, thereby reducing binary development risk and creating multiple near-term clinical and regulatory milestones. In parallel, Patrys is advancing its deoxymab platform with a comprehensive preclinical program in collaboration with Monash University to validate PAT-DX1 and PAT-DX3 in immune-mediated inflammatory diseases, including ANCA-associated vasculitis, through disease-relevant models, comparative studies against standard-of-care therapies and NET inhibitors, and detailed safety and immune-function assessments. Together with a quarter-end cash balance of $1.9 million supported by a recent capital raise and R&D tax refund, these initiatives are intended to rebalance Patrys’ portfolio between near-term pharmaceutical opportunities and longer-term biologics, strengthening its clinical-stage profile and supporting future regulatory and partnering discussions.
More about Patrys Limited
Patrys Limited is an ASX-listed therapeutic antibody development company focused on biologics, particularly its deoxymab antibody platform, targeting immune-mediated inflammatory and autoimmune diseases. The company is now broadening its scope into central nervous system (CNS) therapeutics through the acquisition of a clinical-stage pharmaceutical asset aimed at delirium in ICU, aged-care and palliative-care settings, complementing its longer-term biologics programs and diversifying its development portfolio.
Average Trading Volume: 493,914
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$10.22M
For an in-depth examination of PAB stock, go to TipRanks’ Overview page.